These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 23925001)

  • 1. Nonreplicating vectors in HIV vaccines.
    Johnson JA; Barouch DH; Baden LR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):412-20. PubMed ID: 23925001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel adenovirus vector-based vaccines for HIV-1.
    Barouch DH
    Curr Opin HIV AIDS; 2010 Sep; 5(5):386-90. PubMed ID: 20978378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
    Gray GE; Moodie Z; Metch B; Gilbert PB; Bekker LG; Churchyard G; Nchabeleng M; Mlisana K; Laher F; Roux S; Mngadi K; Innes C; Mathebula M; Allen M; McElrath MJ; Robertson M; Kublin J; Corey L;
    Lancet Infect Dis; 2014 May; 14(5):388-96. PubMed ID: 24560541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of replication-competent viral vectors for HIV vaccine delivery.
    Parks CL; Picker LJ; King CR
    Curr Opin HIV AIDS; 2013 Sep; 8(5):402-11. PubMed ID: 23925000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
    Bekker LG; Moodie Z; Grunenberg N; Laher F; Tomaras GD; Cohen KW; Allen M; Malahleha M; Mngadi K; Daniels B; Innes C; Bentley C; Frahm N; Morris DE; Morris L; Mkhize NN; Montefiori DC; Sarzotti-Kelsoe M; Grant S; Yu C; Mehra VL; Pensiero MN; Phogat S; DiazGranados CA; Barnett SW; Kanesa-Thasan N; Koutsoukos M; Michael NL; Robb ML; Kublin JG; Gilbert PB; Corey L; Gray GE; McElrath MJ;
    Lancet HIV; 2018 Jul; 5(7):e366-e378. PubMed ID: 29898870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus vaccine trials.
    O'Connell RJ; Kim JH; Corey L; Michael NL
    Cold Spring Harb Perspect Med; 2012 Dec; 2(12):a007351. PubMed ID: 23209178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.
    Walsh SR; Moodie Z; Fiore-Gartland AJ; Morgan C; Wilck MB; Hammer SM; Buchbinder SP; Kalams SA; Goepfert PA; Mulligan MJ; Keefer MC; Baden LR; Swann EM; Grant S; Ahmed H; Li F; Hertz T; Self SG; Friedrich D; Frahm N; Liao HX; Montefiori DC; Tomaras GD; McElrath MJ; Hural J; Graham BS; Jin X;
    J Infect Dis; 2016 Feb; 213(4):541-50. PubMed ID: 26475930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The "STEP-wise" future of adenovirus-based HIV vaccines.
    Patterson LJ
    Curr Med Chem; 2011; 18(26):3981-6. PubMed ID: 21824093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
    Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
    Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
    Moodie Z; Walsh SR; Laher F; Maganga L; Herce ME; Naidoo S; Hosseinipour MC; Innes C; Bekker LG; Grunenberg N; Mann P; Yu C; deCamp AC; Miner MD; Yates NL; Heptinstall J; Mkhize NN; Dintwe O; Frahm N; Cohen KW; Allen M; Hutter J; Wagner R; Pantaleo G; McElrath MJ; Tomaras GD; Morris L; Montefiori DC; Andersen-Nissen E; Gray GE; Gilbert PB; Kublin JG;
    PLoS Med; 2020 May; 17(5):e1003117. PubMed ID: 32442195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Specific B and T Cell Immune Functions in Nonhuman Primates.
    García-Arriaza J; Perdiguero B; Heeney JL; Seaman MS; Montefiori DC; Yates NL; Tomaras GD; Ferrari G; Foulds KE; Roederer M; Self SG; Borate B; Gottardo R; Phogat S; Tartaglia J; Barnett SW; Burke B; Cristillo AD; Weiss DE; Lee C; Kibler KV; Jacobs BL; Wagner R; Ding S; Pantaleo G; Esteban M
    J Virol; 2017 May; 91(9):. PubMed ID: 28179536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine.
    Gray G; Buchbinder S; Duerr A
    Curr Opin HIV AIDS; 2010 Sep; 5(5):357-61. PubMed ID: 20978374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cells induced by recombinant chimpanzee adenovirus alone and in prime-boost regimens decrease chimeric EcoHIV/NDK challenge virus load.
    Roshorm Y; Cottingham MG; Potash MJ; Volsky DJ; Hanke T
    Eur J Immunol; 2012 Dec; 42(12):3243-55. PubMed ID: 22930183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenoviruses as vectors for HIV vaccines.
    Gómez-Román VR; Robert-Guroff M
    AIDS Rev; 2003; 5(3):178-85. PubMed ID: 14598567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III HIV vaccine trial in Thailand: a step toward a protective vaccine for HIV.
    Vaccari M; Poonam P; Franchini G
    Expert Rev Vaccines; 2010 Sep; 9(9):997-1005. PubMed ID: 20822342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials.
    Huang Y; Follmann D; Nason M; Zhang L; Huang Y; Mehrotra DV; Moodie Z; Metch B; Janes H; Keefer MC; Churchyard G; Robb ML; Fast PE; Duerr A; McElrath MJ; Corey L; Mascola JR; Graham BS; Sobieszczyk ME; Kublin JG; Robertson M; Hammer SM; Gray GE; Buchbinder SP; Gilbert PB
    PLoS One; 2015; 10(9):e0136626. PubMed ID: 26332672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ebola virus vaccine: benefit and risks of adenovirus-based vectors.
    Mennechet FJ; Tran TT; Eichholz K; van de Perre P; Kremer EJ
    Expert Rev Vaccines; 2015; 14(11):1471-8. PubMed ID: 26325242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lessons from HIV-1 vaccine efficacy trials.
    Excler JL; Michael NL
    Curr Opin HIV AIDS; 2016 Nov; 11(6):607-613. PubMed ID: 27537673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein.
    Wright PF; Mestecky J; McElrath MJ; Keefer MC; Gorse GJ; Goepfert PA; Moldoveanu Z; Schwartz D; Spearman PW; El Habib R; Spring MD; Zhu Y; Smith C; Flores J; Weinhold KJ;
    J Infect Dis; 2004 Apr; 189(7):1221-31. PubMed ID: 15031791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
    Nyombayire J; Anzala O; Gazzard B; Karita E; Bergin P; Hayes P; Kopycinski J; Omosa-Manyonyi G; Jackson A; Bizimana J; Farah B; Sayeed E; Parks CL; Inoue M; Hironaka T; Hara H; Shu T; Matano T; Dally L; Barin B; Park H; Gilmour J; Lombardo A; Excler JL; Fast P; Laufer DS; Cox JH;
    J Infect Dis; 2017 Jan; 215(1):95-104. PubMed ID: 28077588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.